| Literature DB >> 36196373 |
LiHong Xu1, Peng Wang2, YaNi Zhang3, MuQi Wang1, YaPing Li1, WenHui Dang4.
Abstract
Purpose: Chronic obstructive pulmonary disease (COPD) is one of the main risk factors for lung carcinomas. This study aimed to analyze and construct a model to assess scientific publications on the relationship between COPD and lung carcinomas. Patients andEntities:
Keywords: bibliometrics; chronic obstructive pulmonary disease; lung carcinoma; lung neoplasms; visualization analysis
Year: 2022 PMID: 36196373 PMCID: PMC9527034 DOI: 10.2147/IJGM.S370781
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Figure 1Time sequence of relevant papers on COPD and lung cancer published and citations from 2001 to 2021 in Web of Science.
Top 10 Productive Journals in Field of COPD and Lung Cancer
| No. | Journals | Counts | IF2020 |
|---|---|---|---|
| 1 | 62 | 2.74 | |
| 2 | 56 | 12.339 | |
| 3 | 50 | 17.452 | |
| 4 | 45 | 3.486 | |
| 5 | 42 | 2.772 | |
| 6 | 29 | 3.639 | |
| 7 | 27 | 4.702 | |
| 8 | 27 | 3.095 | |
| 9 | 26 | 3.077 | |
| 10 | 26 | 13.357 |
Top 11 Countries/Regions in Terms of Number of Publications and Intermediary Centrality
| Rank. | Country/Region | Counts | Centrality | Year | Country/Region | Counts | Centrality | Year |
|---|---|---|---|---|---|---|---|---|
| 1 | USA | 675 | 0.23 | 1976 | URUGUAY | 2 | 1.31 | 2012 |
| 2 | PEOPLES R CHINA | 256 | 0 | 1997 | SWEDEN | 57 | 0.59 | 1995 |
| 3 | ENGLAND | 222 | 0.04 | 1995 | SAUDI ARABIA. | 7 | 0.41 | 2010 |
| 4 | JAPAN | 168 | 0.04 | 1998 | NEW ZEALAND | 19 | 0.4 | 2007 |
| 5 | SPAIN | 147 | 0 | 1997 | ICELAND. | 4 | 0.34 | 2012 |
| 6 | GERMANY | 122 | 0.1 | 2000 | FINLAND | 18 | 0.33 | 1998 |
| 7 | CANADA | 121 | 0 | 2001 | PAKISTAN. | 7 | 0.3 | 2015 |
| 8 | ITALY | 112 | 0 | 1994 | ISRAEL | 16 | 0.29 | 2001 |
| 9 | NETHERLANDS | 111 | 0.1 | 1997 | SINGAPORE. | 10 | 0.23 | 2008 |
| 10 | SOUTH KOREA | 97 | 0 | 2000 | ESTONIA. | 4 | 0.2 | 2011 |
| 11 | AUSTRALIA | 75 | 0.04 | 1994 | FRANCE | 67 | 0.2 | 1997 |
Figure 2Map of country/region related to COPD and lung cancer research.
Top 10 Institutions in Terms of Number of Publications and Intermediary Centrality
| Rank. | Institution | Counts | Institution | Centrality |
|---|---|---|---|---|
| 1 | Harvard University | 90 | Boston Univ | 0.34 |
| 2 | University of California System | 67 | Harvard Med Sch | 0.3 |
| 3 | University of London | 64 | Univ Edinburgh | 0.3 |
| 4 | US Department of Veterans Affairs | 59 | Harvard Univ | 0.26 |
| 5 | Veterans Health Administration Vha | 58 | Univ British Columbia | 0.25 |
| 6 | Brigham Women S Hospital | 53 | Brigham & Womens Hosp | 0.24 |
| 7 | National Institutes of Health NIH USA | 52 | Univ Liverpool | 0.14 |
| 8 | Johns Hopkins University | 48 | Hlth Effects Inst | 0.14 |
| 9 | Ciber Centro De Investigacion Biomedica En Red | 47 | Mayo Clin | 0.11 |
| 10 | Pennsylvania Commonwealth System of Higher Education (PASSHE) | 46 | Cambridge Biomed Res Ctr | 0.11 |
Figure 3Map of institutions’ collaborations related to COPD and lung cancer research.
Figure 4Map of authors’ collaborations related to COPD and lung cancer research.
Top 18 Keywords in Terms of Frequency and Centrality of COPD and Lung Cancer Research
| Rank. | Keyword | Frequency | Year | Centrality | Keyword | Frequency | Year | Centrality |
|---|---|---|---|---|---|---|---|---|
| 1 | Copd | 560 | 1991 | 0.03 | Asthma | 75 | 1994 | 0.31 |
| 2 | Lung cancer | 440 | 1992 | 0.09 | Adenocarcinoma | 20 | 1997 | 0.22 |
| 3 | Obstructive pulmonary disease | 377 | 1999 | 0.07 | Heart failure | 12 | 2011 | 0.21 |
| 4 | Risk | 351 | 1992 | 0.15 | Bronchogenic carcinoma | 12 | 1991 | 0.2 |
| 5 | Mortality | 270 | 1994 | 0.13 | Care | 27 | 1998 | 0.19 |
| 6 | Disease | 180 | 1991 | 0.18 | Cancer | 135 | 1992 | 0.19 |
| 7 | Expression | 157 | 1996 | 0.05 | Disease | 180 | 1991 | 0.18 |
| 8 | Prevalence | 156 | 1997 | 0.01 | risk | 351 | 1992 | 0.15 |
| 9 | Association | 145 | 1999 | 0.05 | Population | 67 | 1999 | 0.14 |
| 10 | Survival | 141 | 2000 | 0.05 | Alveolar macrophage | 5 | 1996 | 0.13 |
| 11 | Smoking | 140 | 1997 | 0.08 | Death | 48 | 1996 | 0.13 |
| 12 | Cancer | 135 | 1992 | 0.19 | Mortality | 270 | 1994 | 0.13 |
| 13 | Inflammation | 134 | 2007 | 0.02 | Air flow obstruction | 47 | 1997 | 0.11 |
| 14 | Emphysema | 117 | 1997 | 0.05 | Smoker | 82 | 1992 | 0.1 |
| 15 | Diagnosis | 111 | 2002 | 0.04 | Breast cancer | 25 | 1995 | 0.09 |
| 16 | Impact | 110 | 2005 | 0.04 | Air pollution | 33 | 1997 | 0.09 |
| 17 | Management | 103 | 2006 | 0.01 | Gene expression | 34 | 2006 | 0.09 |
| 18 | Risk factor | 100 | 1997 | 0.04 | Biomarker | 42 | 1999 | 0.09 |
Figure 5Co-occurrence cluster atlas in the research of COPD and lung cancer.
Basic Characteristics of the First 6 Main Clusters in the Keywords Cluster Atlas of Literature on COPD and Lung Cancer
| Cluster ID | Sise | Silhouette | Mean (Year) | Cluster (LLR) | Main Keywords |
|---|---|---|---|---|---|
| #0 | 52 | 0.885 | 2003 | Lung disease mortality | Obstructive pulmonary disease, prevalence, smoking, asthma, population, air flow obstruction, cardiovascular disease |
| #1 | 51 | 0.929 | 2003 | Expiratory volume | Mortality, morbidity, therapy, lobectomy, predictor, acute exacerbation, exercise capacity, prediction, bronchogenic carcinoma |
| #2 | 49 | 0.956 | 2002 | Anti-p53 antibodies | Expression, association, smoker, biomarker, breast cancer, adenocarcinoma, Pathway, mutation |
| #3 | 49 | 0.931 | 2004 | Lung cancer chronic | COPD, risk, cancer, exposure, cell, computed tomography, cohort, volatile organic compound, dimension |
| #4 | 45 | 0.897 | 2010 | End-stage chronic | Palliative care, burden, exacerbation, of life care, need, China, heart failure, cancer patient, life, China Taiwan |
| #5 | 43 | 0.941 | 2003 | Retrospective proportional mortality study | Risk factor, cigarette smoking, United States, death, coronary heart disease, never smoker |
Figure 6The critical time diagram based on the clustering results of Figure 5.
Top 25 Keywords with the Strongest Citation Bursts
| Keywords | Year | Strength | Begin | End | 1976–2021 Year |
|---|---|---|---|---|---|
| Bronchogenic carcinoma | 1976 | 6.12 | 2003 | ||
| Cigarette smoking | 1976 | 7.82 | 2007 | ||
| Coronary heart disease | 1976 | 7.37 | 2007 | ||
| Carcinoma | 1976 | 15.15 | 2007 | ||
| Resection | 1976 | 7.36 | 2010 | ||
| Chronic bronchiti | 1976 | 4.63 | 2012 | ||
| Women | 1976 | 6.8 | 2008 | ||
| Inflammation | 1976 | 5.87 | 2009 | ||
| Susceptibility locus | 1976 | 11.26 | 2012 | ||
| Population | 1976 | 6.52 | 2012 | ||
| Variant | 1976 | 7.27 | 2012 | ||
| Genome-wide association | 1976 | 5.42 | 2017 | ||
| Mice | 1976 | 5.56 | 2015 | ||
| Of life care | 1976 | 5.26 | 2018 | ||
| People | 1976 | 4.94 | 2019 | ||
| Long-term exposure | 1976 | 4.91 | 2021 | ||
| Global burden | 1976 | 6.96 | 2021 | ||
| Fine particulate matter | 1976 | 6.2 | 2021 | ||
| pm25 | 1976 | 5.58 | 2021 | ||
| Validation | 1976 | 5.41 | 2019 | ||
| Metaanalysis | 1976 | 5.22 | 2018 | ||
| Air pollution | 1976 | 4.67 | 2021 | ||
| Biomarker | 1976 | 5.05 | 2021 | ||
| Impact | 1976 | 5.6 | 2021 | ||
| Emphysema | 1976 | 5.04 | 2021 |